Cancer and thrombosis revisited

Blood Reviews

Volumn 15, Issue 2, 2001, Pages 61-67

  Hoffman, R ^a   Haim, N ^a   Brenner, B ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; THROMBOPLASTIN;

ARTERY THROMBOSIS; BLOOD CLOTTING; CANCER; CANCER PATIENT; CANCER SURVIVAL; CENTRAL VENOUS CATHETER; DISEASE ASSOCIATION; ENDOTHELIUM; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TUMOR GROWTH; VEIN THROMBOSIS;

EID: 0034930752     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0149     Document Type: Editorial

References (94)

1. Venous thromboembolism in malignancy
2. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors
3. Pathophysiology of the thrombophilic state in the cancer patient
4. Diagnosis of cancer associated vascular disorders
5. Essential thrombocythemia - Update on pathogenesis and therapy
6. Cardiac vascular vegetations in cancer patients: A prospective echocardiographic study of 200 patients
7. Thrombosis and cancer
8. Thrombosis in patients with cancer
9. Hemostatic alterations in cancer patients
10. Abnormalities of blood coagulation in patients with cancer
11. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia
12. Coagulation disorders in cancer
13. Fibrinolysis and cancer
14. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies
15. Tissue factor activity in leukemic cells. Special reference to disseminated intravascular coagulation
16. The tissue factor pathway of blood coagulation
17. Extrinsic-pathway activation in cancer with high factor VII and tissue factor
18. Tissue factor expression in human leukemic cells
19. Elevated tissue factor levels in leukemic cell homogenate
20. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adeno-carcinoma
21. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents
22. Expression of tissue factor in non small cell lung cancers and its relationship to metastasis
23. Tissue factor expression and metastatic potential of colorectal cancer
24. Tissue factor expression and angiogenesis in human prostate carcinoma
25. Tissue factor expression in breast cancer tissues. Its correlation with prognosis and plasma concentration
26. Isolation and characterization of cancer procoagulant: A cysteine protease from malignant tissue
27. Cysteine proteinase procoaulant from amnion-chorion
28. Effect of all trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia
29. Cancer procoagulant in acute non-lymphoid leukemia. Relationship of enzyme detection to disease activity
30. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid
31. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all trans retinoic acid
32. Activation of blood coagulation and the activity of cancer procoagulant (EL 3, 4, 22, 26) in breast cancer
33. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
34. Vascular permeability factor/vascular endothelial growth factor: A multi funcional aniogenesis factor
35. The effect of dexamethasone on pro-inflammatory cytokine expression, cell growth and maturation during granulocytic differentiation of acute promyelocytic leukemia cells
36. Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions
37. Inhibition of angiogenesis and tumor growth by VEGF 121-toxin conjugate: Differential effect on proliferating endothelial cells
38. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma
39. Effects of thrombin / thrombosis in angiogenesis and tumour progression
40. Matrix metalloproteinases in tumor invasion
41. No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer
42. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis
43. Urokinase type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets
44. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von-Willebrand factor on tumor adhesion in-vitro and metastasis in-vivo
45. Tumor interaction with hemostasis: The rationale for use of platelet inhibitors and anticoagulants in treatment of cancer
46. Beta thromboglobulin and platelet factor 4 in patients with cancer. Correlation with the stage of disease and the effect of chemotherapy
47. Circulating activated platelets in myeloproliferative disorders
48. Platelets in tumor metastasis: Generation of ADP by tumor cells is specific but unrelated to metastatic potential
49. Hemostatic abnormalities in untreated cancer. Incidence and correlation with thrombotic and hemorrhagic complications
50. Hemostatic and fibrinolytic responses to bone marrow transplantation
51. Tamoxifen treatment of metastatic breast cancer and AT III levels
52. Deep vein thrombosis and the incidence of subsequent symptomatic cancer
53. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
54. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis
55. Prognosis of cancers associated with venous thromboembolism
56. Deep vein thrombosis of the leg. Is there a 'high risk' group?
57. Pre-operative identification of patients at high risk of deep vein thrombosis after elective major abdominal surgery
58. Prevention of post operative deep leg vein thrombosis in patients with cancer
59. Prevention of venous thromboembolism in cancer patients
60. Thrombophylaxis in the cancer patient
61. Prevention of post-operative deep leg vein thrombosis in patients with cancer
62. Low molecular weight heparin compared to UFH in prevention of postoperative thrombosis
63. Use of LMWH in malignancy
64. Venous thromboembolism in the cancer patient
65. Low molecular weight heparin and uinfractionated heparin in thrombosis prophylaxis after major surgical intervention: Update of previous meta analysis
66. Low molecular weight heparin started before surgery as prophylaxis against DVT: 2500 vs 5000 Xa I units in 2070 patients
67. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery
68. Enoxaparin increases the incidence of post-operative intracranial hemorrhage when inherited preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors
69. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
70. Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomzed prospective trial
71. Upper extremity deep venous thrombosis in cancer patients with venous access devices-Prophylaxis with a low molecular weight heparin (Fragmin)
72. The long-term clinical course of acute deep venous thrombosis
73. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis
74. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread
75. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolism
76. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
77. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis
78. Inhibition of metastases by anticoagulants
79. The use of heparin for treating human malignancies
80. Cancer thrombosis and anticoagulants
81. The influence of anticlotting agents on transplantation and growth of tumor tissue
82. Treatment of deep venous thrombosis with low molecular weight heparins: A metaanalysis
83. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thrombosis. Results of a meta-analysis
84. Heparin and cancer
85. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvis cancer surgery: A prospective randomized double-blind trial
86. Cancer incidence and mortality in patients with heart disease: Effect of oral anticoagulant therapy
87. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial
88. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
89. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
90. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism
91. Progress in anti-angiogenic gene therapy of cancer
92. Angiogenesis in cancer and other diseases
93. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor